MO

ModernaTX, Inc.

Every trial this sponsor leads in the registry, and everything it has published.

95All trials
Recruiting11
Recruited13
Not yet recruiting1
Completed61
Stopped9

25 active · 26% of this sponsor’s registry footprint

Infectious Disease13 trials
Oncology5 trials
Neurology1 trial

Not shown above: 1 Phase 1 healthy-volunteer trial and 5 trials whose condition matched no therapy area.

Trials by phase

Phase 150
Phase 223
Phase 318
Phase 44

Pipeline by phase · 19 drugs in active development

Phase 3 · 2 drugs

mRNA-14032 trialsest. Sept 2026
mRNA-1018-H51 trialest. Jan 2027

Phase 2 · 5 drugs

Intismeran Autogene (mRNA-4157)2 trialsest. Nov 2027
mRNA-11951 trial · 1 recruitingest. Jan 2029
mRNA-12831 trialest. Aug 2029
mRNA-16471 trialest. Mar 2027
mRNA-19821 trialest. Nov 2028

Phase 1 · 10 drugs

mRNA-11892 trials · 1 recruitingest. Oct 2026
mRNA-39272 trials · 2 recruitingest. Aug 2027
mRNA-01841 trial
mRNA-1195.11 trialest. Oct 2026
mRNA-13451 trialest. Aug 2029
mRNA-28081 trial · 1 recruitingest. Jun 2030
mRNA-37051 trial · 1 recruitingest. Apr 2034
mRNA-37451 trialest. Nov 2026

Phase 4 · 2 drugs

Elasomeran (mRNA-1273)1 trialest. Jun 2027
mRNA-1273 Variant-containing Formulation1 trial · 1 recruitingest. Dec 2026

Active trials only, code names and brands merged. 61 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 1 of 10 curated

Multiple myeloma (Oncology)1 trial · 1 recruiting · 1 drug0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon